Leshan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leshan Chen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Huiting Tan
Department of Endocrinology, The First People’s Hospital of Foshan, 528000 Foshan, Guangdong, China
1 shared publication - Jingsong Chen
Department of Endocrinology, The First People’s Hospital of Foshan, 528000 Foshan, Guangdong, China
1 shared publication - Liuyan Ye
The First Clinical Medical College of Guangdong Medical University, 524000 Zhanjiang, Guangdong, China
1 shared publication - Wenzhan Chen
Department of Endocrinology, The First People’s Hospital of Foshan, 528000 Foshan, Guangdong, China
1 shared publication - Xuejuan Xu
Department of Endocrinology, The First People's Hospital of Foshan, Foshan 528000, China
1 shared publication - Youming Chen
The First Clinical Medical College of Guangdong Medical University, 524000 Zhanjiang, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 30 May 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (6) , 36204
Gut Microbiota in Primary Sarcopenia: Mechanisms and Potential Therapeutic Targets
As the global population ages, the risks associated with primary sarcopenia, including falls, fractures, functional decline, and frailty, are becoming increasingly apparent, all of which significantly impair the quality of life in older adults. Emerging evidence suggests that the gut microbiota plays a pivotal role in maintaining muscle physiology. Specific gut bacteria promote intramuscular protein synthesis through the production of certain amino acids (e.g., leucine, tryptophan), short-chain fatty acids (SCFAs), and hydrogen sulfide. Notably, Escherichia coli expressing the enzyme nicotinamidase (PncA) has been shown to enhance nicotinamide adenine dinucleotide (NAD+) synthesis, potentially improving mitochondrial function in muscle tissue. Furthermore, secondary bile acids and lactate influence the levels of fibroblast growth factor 15/19 and unacylated ghrelin in circulation by binding to receptors that are highly expressed in gut endocrine cells, thereby affecting muscle physiology. This review examines the characteristic composition of the gut microbiota in patients with sarcopenia, its role in primary sarcopenia, and potential therapeutic targets.
- 30 May 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (6) , 36204
Open AccessGut Microbiota in Primary Sarcopenia: Mechanisms and Potential Therapeutic Targets
As the global population ages, the risks associated with primary sarcopenia, including falls, fractures, functional decline, and frailty, are becoming increasingly apparent, all of which significantly impair the quality of life in older adults. Emerging evidence suggests that the gut microbiota plays a pivotal role in maintaining muscle physiology. Specific gut bacteria promote intramuscular protein synthesis through the production of certain amino acids (e.g., leucine, tryptophan), short-chain fatty acids (SCFAs), and hydrogen sulfide. Notably, Escherichia coli expressing the enzyme nicotinamidase (PncA) has been shown to enhance nicotinamide adenine dinucleotide (NAD+) synthesis, potentially improving mitochondrial function in muscle tissue. Furthermore, secondary bile acids and lactate influence the levels of fibroblast growth factor 15/19 and unacylated ghrelin in circulation by binding to receptors that are highly expressed in gut endocrine cells, thereby affecting muscle physiology. This review examines the characteristic composition of the gut microbiota in patients with sarcopenia, its role in primary sarcopenia, and potential therapeutic targets.